Replies to post #1658688 on MOMO'S BREAKOUT BOARD

[risingup58]

Excited when the Food and Drug Administration (FDA) a federal agency of the United States Department of Health and Human Services and the National Institute on Drug Abuse (NIDA) funds a Research Study using $XXII low nicotine cigarettes, and then Published by New England Journal of Medicine. It is solid exposure!

XXII owns or exclusively controls more than 185 issued patents and an additional 54 pending patent applications around the world in plant genetics and tobacco harm reduction and smoking cessation products produced from modifying the nicotine content in tobacco plants through genetic engineering.

How much could all these patents (and XXII shares) be worth if 22nd Century gains approval to be the only company allowed to market their cigarettes as a “modified risk product” or “smoking cessation” aid per FDA guidelines?


In FDA's hands now.

Article published in Oct. 2015

http://microcapresearch.com/xxii/